What does Exenatide do?

Exenatide is an FDA-approved GLP-1 receptor agonist. The source describes it as a synthetic 39-amino-acid peptide modeled on exendin-4 from Gila monster saliva, with about 50% sequence similarity to human GLP-1. It is associated with type 2 diabetes care, glucose control, and weight-loss research contexts.

Is Exenatide FDA approved?

Yes. The source lists Exenatide as FDA approved for type 2 diabetes in adults and pediatric patients ages 10-17. It also states that Byetta and Bydureon BCise were discontinued in Oct 2024 and that a generic from Amneal is available.

What side effects are reported for Exenatide?

The source reports nausea as common and also lists vomiting, diarrhea, dizziness, hypoglycemia, injection site reactions, pancreatitis warning, and acute kidney injury. It also notes rare post-marketing acute pancreatitis reports and says use is not recommended in severe kidney impairment. Individual effects can differ by dose, duration, and personal health factors.

What dose information is listed for Exenatide?

The source reports a community dose of 5-10 mcg twice daily or 2 mg weekly, with a range of 5-10 mcg for immediate release or 2 mg for extended release, by subcutaneous injection. It also includes a research/FDA-labeling row for 5-10 mcg twice daily with Byetta and long-term or chronic use. These entries are evidence transcription for review, not dosing guidance.

Weight Loss FDA Approved - approved for specific uses

Exenatide

Also known as: Byetta, Bydureon, Exendin-4

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

FDA-approved GLP-1 receptor agonist based on exendin-4.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

5–10mcg

Subcutaneous injection

Researched for

Diabetes management, weight loss, glucose control

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

FDA-approved receptor listed for type 2 diabetes, including adults and pediatric ages 10-17.
Synthetic 39-amino-acid based on exendin-4, with the source reporting about 50% sequence overlap with human GLP-1.
Associated source dosing entries include 5-10 mcg twice daily for immediate-release use or 2 mg weekly for extended-release use, by injection.
Source research areas include diabetes management, weight loss, and glucose control.
Brand aliases in the source include Byetta and Bydureon; it also notes Byetta and Bydureon BCise discontinuation in Oct 2024 and generic availability from Amneal.

How it's thought to work

Exenatide is reported to act at the receptor. The source links that receptor activity with glucose-dependent insulin secretion, reduced excess glucagon, delayed gastric emptying, and satiety. It also distinguishes Exenatide from native GLP-1 by noting resistance to DPP-4 degradation: native GLP-1 is described as lasting about two minutes, while Exenatide is reported to circulate with an approximately 2.4-hour half-life. For the once-weekly Bydureon formulation, the source describes slow release from polymer microspheres over days.

What the research shows

Where the research stands

The source characterizes Exenatide as an established FDA-approved drug with substantial human clinical experience rather than an experimental compound. It cites peer-reviewed literature, including a 2012 Regulatory Peptides review, for its path from Gila monster venom research to an approved antidiabetic medication. In type 2 diabetes trials, the source reports lower HbA1c and modest weight loss, with nausea identified as the most common side effect and often diminishing over time. It also states that the EXSCEL cardiovascular outcomes trial found once-weekly Exenatide cardiovascularly safe but did not demonstrate a statistically significant reduction in cardiovascular events. Source cautions include rare post-marketing acute pancreatitis reports and lack of recommendation in severe kidney impairment; it also frames Exenatide as an older class option compared with newer agents such as semaglutide and dulaglutide.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA approved for type 2 diabetes in adults and pediatric patients ages 10-17; source also notes Byetta and Bydureon BCise were discontinued Oct 2024 and that an Amneal generic is available. FDA Approved

Typical dosing

CommunityCommunity dataset

5–10 mcg

twice daily or 2 mg weekly

5 mcgfull range seen10 mcg

Community-reported dosing entry; source notes Exenatide was the first approved GLP-1, references Byetta twice daily and Bydureon weekly forms, and states it must be injected. Not medical advice. · Subcutaneous injection

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

5-10 mcg twice daily (Byetta)

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Long-term / chronic use
Administration: Subcutaneous injection

Timing & administration

Best time to take

Before bed or morning, fasted

Follow specific peptide protocol

Food recommendation

Take on an empty stomach

Why this timing?

The source-provided rationale refers to empty-stomach timing for GH-related peptides to support growth hormone release; this appears nonspecific to Exenatide and should be reviewed before use.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Nausea
Vomiting
Diarrhea
Dizziness
Hypoglycemia
Injection site reactions
Pancreatitis
Acute kidney injury

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

The source reports that Exenatide activates the GLP-1 receptor. Reported downstream effects include glucose-dependent insulin release, lower excess glucagon, slower gastric emptying, and increased satiety. It also notes that exendin-4 resists DPP-4 breakdown better than native GLP-1, which has an approximately two-minute lifetime, and that Exenatide has a half-life of about 2.4 hours. The weekly Bydureon form is described as using polymer microspheres for gradual release over several days.

Sequence

His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Exenatide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Exenatide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions